| Patient | Diana Spencer |
|---|---|
| Date of birth | 1997-07-01 |
| Identifiers | MRN HR-ML028-SYN; SSN (made up) 000-28-5197 |
| Document date | 2026-02-16 |
| Author | Imogen Castleford, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-week review with potassium recheck, seen the same day by eating disorders psychiatry. [S]
Ms. Spencer returns one week after her first visit and is seen by Dr. Rosenthal, the eating disorders psychiatrist, on the same day. She has taken potassium chloride 20 mEq twice daily without stomach upset. She has kept the self-monitoring record she was given: seven episodes of binge eating with vomiting this week, from about ten, and breakfast on three days. She has met the dietitian once. She has had no palpitations, cramps, weakness, dizziness, or blood in the vomit. Her mood is still low and she is tired, but she says that telling someone has been a relief. She has had no thoughts of suicide or self-harm. [S]
| Element | Detail |
|---|---|
| Binge eating and vomiting | Seven episodes this week, from about ten |
| Potassium supplement | 20 mEq twice daily, every dose taken |
| Regular eating | Breakfast on three days; dietitian seen once |
| Mood | Low; PHQ-9 13; item 9 scored 0 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the mornings; weight steady |
| Cardiovascular | Negative | No palpitations, chest pain, or fainting |
| Gastrointestinal | Positive | Vomiting after binges seven times this week; no blood in the vomit; no abdominal pain |
| Musculoskeletal | Negative | No cramps or weakness |
| Psychiatric | Positive | Low mood and hopelessness, a little better; no thoughts of suicide or self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Potassium chloride 20 mEq extended-release oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food, swallowed whole with a full glass of water | Oral route | 2026-02-09 to 2026-03-16 | completed | S |
| Fluoxetine 20 mg oral capsule, one capsule by mouth each morning for one week, then two capsules each morning for one week | One capsule each morning for one week, then two capsules each morning for one week | Oral route | 2026-02-16 to 2026-03-02 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-16 | Body height | 178 | cm | S |
| 2026-02-16 | Body weight | 61.2 | kg | S |
| 2026-02-16 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-02-16 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-02-16 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-02-16 | Heart rate | 68 | /min | S |
| 2026-02-16 | Respiratory rate | 14 | /min | S |
| 2026-02-16 | Body temperature | 36.5 | Cel | S |
| 2026-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-16 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-16 | Potassium [Moles/volume] in Serum or Plasma | 3.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-16 | Chloride [Moles/volume] in Serum or Plasma | 99 | mmol/L | 98-107 mmol/L | Normal | S |
| 2026-02-16 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 28 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-02-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-02-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 103 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 13 | {score} | S |
Vital signs recorded on 2026-02-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 61.2 kg, BMI 19.3; lying blood pressure 104/66 and pulse 68, standing 100/64 and pulse 84 after three minutes |
| Head and neck | Both parotid glands enlarged and non-tender, as before; enamel erosion on the inner surfaces of the upper front teeth |
| Skin | Small calluses on the backs of two knuckles of the right hand |
| Psychiatric | Tearful at times but engaged; organized; no psychotic features; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bulimia nervosa, severe: recurrent binge eating, each time with self-induced vomiting, averaging about ten episodes a week for about three years, hidden from everyone; self-worth tied closely to body shape and weight; no laxatives, diuretics, diet pills, or excessive exercise. SCOFF 4 of 5; EDE-Q global score 3.9. Findings: bilateral parotid enlargement, enamel erosion on the inner surfaces of the upper front teeth, calluses on the backs of two knuckles of the right hand, a pulse rise of 22 per minute on standing, low potassium and chloride with a raised bicarbonate, and a raised amylase; BMI 19.3. Synthetic modern episode linked to her own public account of bulimia | active | confirmed | F50.23 | S — Synthetic modern diagnosis by DSM-5-TR criteria; severity is graded by the average number of compensatory episodes a week (8 to 13 is severe). |
| Hypokalemia (potassium 3.1 mmol/L) with low chloride and metabolic alkalosis from repeated vomiting; QTc 452 ms; no palpitations, weakness, or fainting | active | confirmed | E87.6 | S — Synthetic presenting laboratory finding; resolved when potassium was normal on two checks. |
| Major depressive disorder, recurrent, moderate: about two months of low mood, tiredness, poor sleep, and feeling worthless and hopeless, with little pleasure in things she used to enjoy; PHQ-9 14 with item 9 scored 0; an earlier episode of depression after childbirth. Synthetic modern episode linked to her own public account of depression | active | confirmed | F33.1 | S — Synthetic modern diagnosis; the earlier episode is the post-natal depression she described publicly. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Binge-eating and vomiting frequency (her self-monitoring record) | Every visit | Completed today | Seven episodes of binge eating with vomiting this week, from about ten |
| Survey | Eating Disorder Examination Questionnaire (EDE-Q) global score | Baseline, mid-treatment, and end of treatment | Up to date | Global score 3.9 at intake; repeat at mid-treatment |
| Examination | Weight and BMI | Every visit, and weekly in CBT-E sessions | Completed today | 61.2 kg, BMI 19.3 |
| Examination | Lying and standing pulse and blood pressure | Every visit while purging continues | Completed today | Lying 104/66, pulse 68; standing 100/64, pulse 84 (rise 16) |
| Laboratory | Potassium, chloride, bicarbonate, and creatinine | Weekly until potassium is normal twice, then at each medical visit while purging continues | Completed today | Potassium 3.6 mmol/L, from 3.1; sodium 139, chloride 99, bicarbonate 28 mmol/L; creatinine 0.80 mg/dL, eGFR 103 |
| Laboratory | Magnesium and phosphate | Baseline, and again while potassium is low | Up to date | Magnesium 1.8 and phosphate 3.4 mg/dL at intake; magnesium again at the next visit |
| Laboratory | ECG with QTc | Baseline with purging or low potassium; after a QT-relevant medicine reaches its full dose while potassium has been low | Due | QTc 452 ms at intake; repeat two weeks after reaching fluoxetine 60 mg |
| Examination | Parotid and dental examination; dental protection | Every visit; a dental examination soon after diagnosis and regular dental reviews while vomiting continues | Due | Parotid enlargement and enamel erosion unchanged; dental examination advised at intake, not yet booked |
| Medication safety | Oral potassium supplement | While potassium is low or vomiting is frequent | Completed today | 20 mEq twice daily, every dose taken; continue until a second normal check |
| Medication safety | Fluoxetine dose, adherence, and side effects (nausea, sleep, agitation, sexual effects, suicidal thoughts) | At the start, one to two weeks after starting or a dose change, then every visit | Completed today | Starting today at 20 mg; side effects, agitation and suicidal thoughts explained; nurse phone check in ten days |
| Referral | Eating disorders psychiatry consultation | At diagnosis | Completed today | Seen by Dr. Rosenthal today |
| Self-management | CBT-E attendance and progress | Up to 20 sessions over 20 weeks, twice weekly for the first four weeks | Ordered | CBT-E starts this week |
| Self-management | Regular eating and dietitian review | Every visit | Completed today | Breakfast on three days; dietitian seen once |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, then periodically | Completed today | PHQ-9 13, item 9 scored 0 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; no firearm |
| Examination | Level-of-care review against thresholds for urgent or inpatient care | Every visit | Completed today | Outpatient care remains safe: potassium above 3.0 mmol/L, QTc below 500 ms, no fainting, pulse above 50 |
Goal progress:
Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders, Fourth Edition (2023); Eating disorders: recognition and treatment (NICE guideline NG69) (2017, updated 2020); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: CBT-E twice weekly from this week. Nurse phone check in ten days. Visit in four weeks with electrolytes, magnesium, ECG, and the PHQ-9. Next scheduled visit 2026-03-16: five-week review: potassium and ECG on fluoxetine 60 mg, CBT-E progress, mood, and safety. [S]